



## **Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets**

May 1, 2025

SAN FRANCISCO, May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. [\\_](#)

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: <https://ir.nektar.com/>. The web broadcast of the conference call will be available for replay through June 8, 2025.

To access the conference call, please pre-register at [Nektar Earnings Call Registration](#). All registrants will receive dial-in information and a PIN allowing them to access the live call.

### **About Nektar Therapeutics**

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit [www.nektar.com](http://www.nektar.com) and follow Nektar on LinkedIn.


### **Contacts:**

#### **For Investors:**

Ahu Demir, Ph.D.  
LifeSci Advisors, LLC  
[ademir@lifesciadvisors.com](mailto:ademir@lifesciadvisors.com)  
212-915-3820

#### **For Media:**

Madelin Hawtin  
LifeSci Communications 603-714-2638  
[mhawtin@lifescicomms.com](mailto:mhawtin@lifescicomms.com)

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-on-thursday-may-8-2025-after-close-of-us-based-financial-markets-302443436.html>

SOURCE Nektar Therapeutics